Followers | 144 |
Posts | 27707 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, October 06, 2017 11:37:55 AM
Posted by Toi Williams on Oct 6th, 2017
https://www.truebluetribune.com/2017/10/06/redhill-biopharma-ltd-rdhl-given-average-recommendation-of-buy-by-brokerages.html
Redhill Biopharma Ltd. (NASDAQ:RDHL) has received a consensus rating of “Buy” from the six analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $31.50.
A number of equities research analysts recently weighed in on RDHL shares. HC Wainwright set a $33.00 price objective on shares of Redhill Biopharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Roth Capital set a $27.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research lowered shares of Redhill Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, July 29th. Seaport Global Securities began coverage on shares of Redhill Biopharma in a research note on Friday. They set a “buy” rating for the company. Finally, FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a research report on Friday, June 16th.
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/18/2024 01:00:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/17/2024 01:13:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/09/2024 11:04:47 AM
- RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines • PR Newswire (US) • 09/09/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 12:30:10 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/05/2024 11:05:46 AM
- RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement • PR Newswire (US) • 09/05/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/03/2024 11:03:23 AM
- New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality • PR Newswire (US) • 09/03/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/29/2024 11:07:16 AM
- RedHill Biopharma Announces First Half 2024 Business Highlights • PR Newswire (US) • 08/29/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/26/2024 11:02:21 AM
- RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma • PR Newswire (US) • 08/26/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/21/2024 11:04:32 AM
- Talicia® Launched in the United Arab Emirates • PR Newswire (US) • 08/21/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/20/2024 04:15:08 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 11:01:08 AM
- RedHill Announces Positive Obesity and Diabetes Results with Opaganib • PR Newswire (US) • 08/19/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2024 11:13:47 AM
- RedHill Biopharma Announces Plan to Implement ADS Ratio Change • PR Newswire (US) • 08/16/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/13/2024 05:37:51 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:35:44 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/09/2024 11:01:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/07/2024 01:51:39 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM